Results 101 to 110 of about 7,787 (204)

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment

BMC Infectious Diseases, 2013
Background With declining vectorial transmission, Chagas disease predominantly affects adults nowadays. The efficacy of nifurtimox in the chronic phase in adult patients is poorly known, particularly in regions where there is no risk of reinfection ...
Jackson Yves, Chatelain Eric, Mauris Anne, Holst Marylise, Miao Qianqian, Chappuis Francois, Ndao Momar   +6 more
doaj   +1 more source

ISEV2025 Abstract Book

Journal of Extracellular Vesicles, Volume 14, Issue S1, October 2025.
wiley   +1 more source

Efeito protetor do nifurtimox contra a reativação parasitária em pacientes cronicamente infectados pelo Trypanosoma cruzi e tratados com corticóide em virtude de afecções associadas

Revista da Sociedade Brasileira de Medicina Tropical, 1998
Pacientes na fase crônica da doença de Chagas foram tratados com corticóide em virtude de afecções associadas e, a fim de tentar coibir reativação da infecção pelo Trypanosoma cruzi, houve uso concomitante do nifurtimox.
Anis Rassi, Vicente Amato Neto, Astolpho Ferraz de Siqueira, Maurício Sérgio Brasil Leite   +3 more
doaj  

Tratamento da fase crônica da doença de Chagas com nifurtimox associado a corticóide

Revista da Sociedade Brasileira de Medicina Tropical, 2002
Dez pacientes com doença de Chagas em fase crônica foram tratados durante 60 dias, com uma única exceção, por meio de nifurtimox (8 a 9mg/kg/dia) conjuntamente com betametasona (doses progressivamente decrescentes a partir de 9mg/dia).
Anis Rassi, Vicente Amato Neto, Astolpho Ferraz de Siqueira, Francisco Ferriolli Filho, Valdir Sabbaga Amato, Gustavo Gabriel Rassi, Anis Rassi Junior   +6 more
doaj  

Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the Congo [PDF]

, 2017
Since 2009, nifurtimox-eflornithine combination therapy (NECT) has raised great hopes for the treatment of second-stage human African trypanosomiasis.
Alirol, Emilie, Amici Heradi, Josué, Chappuis, François, de Patoul, Catherine, Quere, Michel, Riedel, Andrea, Schrumpf, David   +6 more
core  

Human African trypanosomiasis in endemic populations and travellers [PDF]

, 2018
Human African trypanosomiasis (HAT) or sleeping sickness is caused by the protozoan parasites Trypanosoma brucei (T.b.) gambiense (West African form) and T.b.
Blum, J., Hatz, C., Neumayr, A.
core  

A Expressão Global da Doença de Chagas – Oportunidades Emergentes e Impacto em Portugal [PDF]

, 2012
Chagas disease, caused by the protozoan Trypanosoma cruzi is endemic in the countries of Central and South America. Despite vector control programs and other measures taken in the blood banks and maternity hospitals, it is estimated that there are about ...
Cortez, J, Ramos, E, Seixas, J, Valente, C, Vieira, A   +4 more
core  

Melarsoprol-Free Drug Combinations for Second-Stage Gambian Sleeping Sickness: The Way to Go. [PDF]

, 2007
Balasegaram, Brun, F. Chappuis, Priotto, P  pin, P  pin, Van Nieuwenhove   +6 more
core   +2 more sources

Chagas disease. [PDF]

CMAJ
Billick MJ, Silverberg SL.
europepmc   +2 more sources

Parasitic diseases in heart transplantation: challenges of Toxoplasmosis and Chagas Disease. [PDF]

JHLT Open
Tejo AM, Campos SV.
europepmc   +1 more source